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Background:  ART initiation
in the 3rd trimester of pregnancy is associated with failure to achieve viral
suppression (VS) by delivery and increased transmission of HIV. We randomised 60 treatment naïve pregnant
women at 28-36w gestation in Uganda and South Africa 1:1 to receive EFV or DTG+2NRTIs.
The primary endpoint was pharmacokinetics (PK) of DTG in women and breastfed
infants; secondary endpoints included VS.
Methods:  To comply
with national guidelines, EFV+2NRTI was initiated on referral, with subjects
randomized to DTG switched within 7 days. Viral load (VL) was collected at
every visit; intensive maternal PK sampling (0-24h) was performed at 14 days on
DTG, and 2 weeks post-partum, with paired sampling between maternal plasma and
cord blood, breastmilk and infant plasma. All infants were exclusively
breastfed.
Results:  There was
no significant pre-ART differences between DTG (n=29) and EFV (n=31) arms in
maternal age, gestation at treatment initiation (30.8w), weight, obstetric
history, VL (log 4 copies) and CD4 count (394 cells/mm3). Third
trimester DTG exposures were low with C<sub>trough</sub> at or below target (MEC 324ng/mL)
in 9/28 (32%) mothers. DTG transfer across the placenta (122%) and in breast
milk (3%) coupled with delayed elimination resulted in significant infant exposures
potentially persisting during breast-feeding. Both regimens were
well-tolerated. A total of 10 SAEs were reported in 5 mothers and 3 infants,
with no significant differences between arms.
 Superior VS was observed with DTG (Table 1) at
the 2w post-partum visit (P=0.005). However, VL>1000 copies/mL near delivery
was still observed with both DTG (3.7%) and EFV (7.4%). No HIV transmissions
were observed
Conclusions:  HIV RNA suppression < 50
copies/mL was more rapid with DTG (despite low DTG exposures when started in the
third trimester) which may translate to improved PMTCT for ART initiation in
late pregnancy. The impact of significant infant DTG exposures related to
intrauterine transfer, continued breastfeeding and delayed elimination is being evaluated in the DolPHIN-2 study.
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